Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Longitudinal Therapy Response Monitoring Study in Subjects With Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging).

NCT05414123 is registered in ClinicalTrials.gov with Biocept, Inc. as lead sponsor.

NCT NCT05414123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05414123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Longitudinal Therapy Response Monitoring Study in Subjects With Leptomeningeal Metastases Using CNSide (CSF Tumor Cells) Compared to Standard of Care (CSF Cytology, Clinical Evaluation, and Imaging).
Lead sponsor
Biocept, Inc.
Phase
Observational
Overall status
Terminated
Start date
September 7, 2022
Completion date
October 13, 2023
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, leptomeningeal disease, leptomeningeal metastasis, leptomeningeal neoplasms, non-small cell lung cancer